A Phase 1 interventional study of Etanercept and Denosumab in Postmenopausal, Osteopenia and Rheumatoid Arthritis, sponsored by Amgen. Terminated at 2 sites in United States. Open to female participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-06-20.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.
Among the 64 studies testing denosumab in Osteoporosis, this one is the 56th largest by enrollment, is one of 3 that started in 2011, is one of 5 in phase 1, and was the 19th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 50–85 · Women only
Aarhus University Hospital · Sites in Denmark
Ages 40+ · Women only
Chrissy Kistler · Sites in United States
Ages 65+
Wuhan Union Hospital, China · Sites in China
Ages 40+
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 45 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 25 · Phase 4 19
First in 2002; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 90 across the 64 interventional studies. Of the 45 that completed or were terminated, 32 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 64 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
34 studies in Osteoporosis by Amgen: none open now, 2 under way, none of them phase 3. Of 32 finished, 31 (97%) have results posted.
Among the 34 studies in Osteoporosis by Amgen, this one is the 30th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2011, is one of 5 in phase 1, and was the 18th registered.
Amgen’s Osteoporosis studies by the year they started, since 2002.
6 of the studies testing denosumab in Osteoporosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062978Phase 3Qilu Pharmaceutical Co., Ltd.A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | 2027-01 |
| NCT06332014AmgenEvaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China | 2027-01-23 |
| NCT04608630Australian and New Zealand Intensive Care Research CentreBone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults | 2027-02-28 |
| NCT04800367Columbia UniversityRomosozumab/Denosumab Study for Premenopausal IOP | 2027-03 |
| NCT07271771Aarhus University HospitalThe Effect of Denosumab on Muscle and Strength and Insulin Sensitivity | 2027-03-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies testing denosumab in Osteoporosis, from their registry updates:
Among Amgen’s 34 in Osteoporosis:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to characterize the effects of a single dose of denosumab on the pharmacokinetics (PK) of etanercept in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis based on area under the serum concentration-time curve (AUC) and maximum observed serum concentration (Cmax).
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
This study's enrollment of 19 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Browse Osteoporosis studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Osteoporosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bone Diseases, Metabolic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received etanercept 50 mg subcutaneously once weekly for 25 weeks. On study day 8, participants were administered a single 60 mg subcutaneous injection of denosumab.
Drug: Etanercept · Drug: Denosumab
Administered by subcutaneous injection once a week
Also known as: Enbrel®
Administered by subcutaneous injection
Also known as: Prolia®
Area Under the Serum Concentration-time Curve From 0 to 168 Hours (AUC0-168) for Etanercept
The AUC0-168 of etanercept was measured when administered alone (assessed from day 1) and after administration with denosumab (assessed from day 22, 14 days after denosumab dosing, close to the time of the maximum observed denosumab serum concentration and corresponding to a time approximately 1 week after maximal pharmacodynamic (PD) effects of denosumab are attained).
Time frame: Day 1 and day 22; at each time point samples were taken predose and 2, 3, 4, 5, 6 and 8 days postdose.
Maximum Observed Serum Concentration (Cmax) of Etanercept
Time frame: Day 1 and day 22; at each time point samples were taken predose and 2, 3, 4, 5, 6 and 8 days postdose.
Time to Maximum Serum Concentration (Tmax) of Etanercept
Time frame: Day 1 and day 22; at each time point samples were taken predose and 2, 3, 4, 5, 6 and 8 days postdose.
Serum Denosumab Concentration
Time frame: Prior to etanercept and denosumab dose administrations, as applicable, on days 8, 22, and 29
Percent Change From Baseline in Serum C-telopeptide (sCTx) Concentrations
Time frame: Baseline (Day 8) and Days 22, 29, 85, and 176
This study was conducted at 2 centers in the United States. The first participant enrolled on 07 March 2011; the last participant was enrolled on 15 June 2015.
| Milestone | Etanercept + Denosumab |
|---|---|
| Started | 19 |
| Completed | 17 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Administrative decision | 1 |
The AUC0-168 of etanercept was measured when administered alone (assessed from day 1) and after administration with denosumab (assessed from day 22, 14 days after denosumab dosing, close to the time of the maximum observed denosumab serum concentration and corresponding to a time approximately 1 week after maximal pharmacodynamic (PD) effects of denosumab are attained).
| day*μg/mL | Etanercept + Denosumab |
|---|---|
| Etanercept Alone (Day 1) | 40.8 ± 18.8 |
| Etanercept + Denosumab (Day 22) | 40.4 ± 26.6 |
| μg/mL | Etanercept + Denosumab |
|---|---|
| Etanercept Alone - Day 1 (n=19) | 8.71 ± 5.47 |
| Etanercept + Denosumab - Day 22 (n=18) | 8.25 ± 5.57 |
| days | Etanercept + Denosumab |
|---|---|
| Etanercept Alone - Day 1 (n=19) | 3.0 (0.99 to 4.9) |
| Etanercept + Denosumab - Day 22 (n=18) | 2.0 (0.93 to 4.9) |
| μg/mL | Etanercept + Denosumab |
|---|---|
| Day 8 (n=19) | 0.00 ± 0.00 |
| Day 22 (n=18) | 5.30 ± 1.35 |
| Day 29 (n=18) | 4.85 ± 1.35 |
| percent change | Etanercept + Denosumab |
|---|---|
| Day 22 (n = 18) | -32.3 (-58.7 to 0.0) |
| Day 29 (n = 18) | -32.3 (-60.9 to 0.0) |
| Day 85 (n = 17) | -26.2 (-60.9 to 0.0) |
| Day 176/End of Study (n = 19) | -25.1 (-60.4 to 0.0) |
Collected over From first dose of etenercept in the run-in period (day -28) until end of study (day 176).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Etanercept 50 mg Day - 28 - Day 7 | — | 0/19 (0%) | 13/19 (68.4%) |
| Etanercept 50 mg + Denosumab 60 mg Day 8 - EOS | — | 0/19 (0%) | 2/19 (10.5%) |
| All Subjects On-study | — | 0/19 (0%) | 13/19 (68.4%) |
| Event | Etanercept 50 mg Day - 28 - Day 7 | Etanercept 50 mg + Denosumab 60 mg Day 8 - EOS | All Subjects On-study |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/19 | 0/19 | 3/19 |
| Urinary tract infectionInfections and infestations | 2/19 | 0/19 | 2/19 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/19 | 0/19 | 2/19 |
| ErythemaSkin and subcutaneous tissue disorders | 2/19 | 0/19 | 2/19 |
| Eye haemorrhageEye disorders | 1/19 | 0/19 | 1/19 |
| DiarrhoeaGastrointestinal disorders | 1/19 | 0/19 | 1/19 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 1/19 | 0/19 | 1/19 |
| Injection site erythemaGeneral disorders | 1/19 | 0/19 | 1/19 |
| Injection site pruritusGeneral disorders | 1/19 | 0/19 | 1/19 |
| NoduleGeneral disorders | 1/19 | 0/19 | 1/19 |
| Age, Continuous(years) | Etanercept + Denosumab |
|---|---|
| Mean | 63.1 ± 6.6 |
| Sex: Female, Male(Participants) | Etanercept + Denosumab |
|---|---|
| Female | 19 |
| Male | 0 |
| Race/Ethnicity, Customized(participants) | Etanercept + Denosumab |
|---|---|
| Hispanic/Latino | 1 |
| Not Hispanic/Latino | 18 |
| Race/Ethnicity, Customized(participants) | Etanercept + Denosumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Black (or African American) | 1 |
| Mixed race | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| White | 18 |
The record gives a start of Mar 2011, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Etanercept · Denosumab